Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metalloproteinase activity in head and neck carcinoma

Oral Oncology

Volumn 51, Issue 5, 2015, Pages 470-475

  Raju, Sharat C ^a   Hauff, Samantha J ^a   Lemieux, Aaron J ^a   Orosco, Ryan K ^a   Gross, Andrew M ^a   Nguyen, Linda T ^a   Savariar, Elamprakash ^b   Moss, William ^a   Whitney, Michael ^b   Cohen, Ezra E ^c   Lippman, Scott M ^c   Tsien, Roger Y ^b,d   Ideker, Trey ^a   Advani, Sunil J ^a   Nguyen, Quyen T ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California San Diego   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

"double hit"; "single hit"; 3p deletion; Double stranded DNA breaks; FHIT; Head and neck cancer; Matrix metalloproteinases; Radiosensitivity; RNA interference; TP53 mutation

Indexed keywords

CELL PENETRATING PEPTIDE; CISPLATIN; DOUBLE STRANDED DNA; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; PROTEIN P53; RATIOMETRIC ACTIVATABLE CELL PENETRATING PEPTIDE; RNA; UNCLASSIFIED DRUG; ACID ANHYDRIDE HYDROLASE; FRAGILE HISTIDINE TRIAD PROTEIN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL LINE; CANCER RADIOTHERAPY; CHROMOSOME 3P; CHROMOSOME LOSS; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMAGE PROCESSING; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; RNA INTERFERENCE; TUMOR XENOGRAFT; CARCINOMA, SQUAMOUS CELL; CHROMOSOME 3; CHROMOSOME DELETION; ENZYMOLOGY; GENETICS; HEAD AND NECK NEOPLASMS; METABOLISM; MUTATION; RADIATION TOLERANCE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ACID ANHYDRIDE HYDROLASES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 3; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; MATRIX METALLOPROTEINASES; MUTATION; NEOPLASM PROTEINS; RADIATION TOLERANCE;

EID: 84933680084     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2015.01.014     Document Type: Article

References (19)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893-917.
2. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. Am Joint Comm Cancer 2010.
3. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004;31(6):744-54.
4. Benson E, Li R, Eisele D, Fakhry C. The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas. Oral Oncol 2014;50(6):565-74.
5. Chaturvedi AK. Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol 2012;6(suppl 1):S16-24.
6. Gross AM, Orosco RK, Shen JP, et al. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet 2014;46(9):939-43.
7. Gollin SM. Cytogenetic alterations and their molecular genetic correlates in head and neck squamous cell carcinoma: a next generation window to the biology of disease. Genes Chromosom Cancer 2014;53(12):972-90.
8. Andriani F, Roz E, Caserini R, et al. Inactivation of both FHIT and p53 cooperate in deregulating proliferation-related pathways in lung cancer. J Thorac Oncol 2012;7(4):631-42.
9. Hu B, Han SY, Wang X, et al. Involvement of the FHIT gene in the ionizing radiation-activated ATR/CHK1 pathway. J Cell Physiol 2005;202(2):518-23.
10. Olson ES, Aguilera TA, Jiang T, et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol (Camb) 2009;1(5-6):382-93.
11. Aguilera TA, Olson ES, Timmers MM, Jiang T, Tsien RY. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb) 2009;1(5-6):371-81.
12. Savariar EN, Felsen CN, Nashi N, et al. Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides. Cancer Res 2013;73(2):855-64.
13. Nguyen QT, Olson ES, Aguilera TA, et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci USA 2010;107(9):4317-22.
14. Hauff SJ, Raju SC, Orosco RK, et al. Matrix-metalloproteinases in head and neck carcinoma-cancer genome atlas analysis and fluorescence imaging in mice. Otolaryngol Head Neck Surg 2014;151(4):612-8.
15. Uloza V, Liutkevičius V, Pangonytė D, Saferis V, Lesauskaitė V. Expression of matrix metalloproteinases (MMP-2 and MMP-9) in recurrent respiratory papillomas and laryngeal carcinoma: clinical and morphological parallels. Eur Arch Otorhinolaryngol 2011;268(6):871-8.
16. Wittekindt C, Jovanovic N, Guntinas-lichius O. Expression of matrix metalloproteinase-9 (MMP-9) and blood vessel density in laryngeal squamous cell carcinomas. Acta Otolaryngol 2011;131(1):101-6.
17. Liu WW, Zeng ZY, Wu QL, Hou JH, Chen YY. Overexpression of MMP-2 in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Otolaryngol Head Neck Surg 2005;132(3):395-400.
18. Mallis A, Teymoortash A, Mastronikolis NS, Werner JA, Papadas TA. MMP-2 expression in 102 patients with glottic laryngeal cancer. Eur Arch Otorhinolaryngol 2012;269(2):639-42.
19. Zhou CX, Gao Y, Johnson NW, Gao J. Immunoexpression of matrix metalloproteinase-2 and matrix metalloproteinase-9 in the metastasis of squamous cell carcinoma of the human tongue. Aust Dent J 2010;55(4):385-9.